Listed

CVS HEALTH Corp: Form 10-Q for the period ended Sep 30, 2018

Filed with the SEC on Nov 6, 2018 and accepted by EDGAR at Nov 6, 2018, 16:28 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-07-01 to 2018-09-30$47.27bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2018-01-01 to 2018-09-30$139.67bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2018-07-01 to 2018-09-30$39.94bnus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2018-01-01 to 2018-09-30$118.28bnus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2018-07-01 to 2018-09-30$7.33bnus-gaap:GrossProfit
Gross profit9 months2018-01-01 to 2018-09-30$21.39bnus-gaap:GrossProfit
Operating income3 months2018-07-01 to 2018-09-30$2.35bnus-gaap:OperatingIncomeLoss
Operating income9 months2018-01-01 to 2018-09-30$2.71bnus-gaap:OperatingIncomeLoss
Income tax3 months2018-07-01 to 2018-09-30$509.0mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2018-01-01 to 2018-09-30$1.48bnus-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-07-01 to 2018-09-30$1.39bnus-gaap:NetIncomeLoss
Net income9 months2018-01-01 to 2018-09-30−$175.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-07-01 to 2018-09-30$1.36us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2018-01-01 to 2018-09-30−$0.17us-gaap:EarningsPerShareDiluted
Basic EPS3 months2018-07-01 to 2018-09-30$1.36us-gaap:EarningsPerShareBasic
Basic EPS9 months2018-01-01 to 2018-09-30−$0.17us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2018-07-01 to 2018-09-301,022,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2018-01-01 to 2018-09-301,018,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2018-01-01 to 2018-09-30$6.39bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2018-01-01 to 2018-09-30$1.45bnus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2018-01-01 to 2018-09-30$1.53bnus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2018-09-30$41.59bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-09-30$71.98bnus-gaap:AssetsCurrent
Total assetsAt period end2018-09-30$131.51bnus-gaap:Assets
Current liabilitiesAt period end2018-09-30$29.46bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-09-30$94.88bnus-gaap:Liabilities
Long-term debtAt period end2018-09-30$60.75bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2018-09-30$2.14bnus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2018-09-30$36.62bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-18-008642. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.